Edwards Lifesciences (NYSE:EW) Lowered to Hold at Jefferies Financial Group

Jefferies Financial Group lowered shares of Edwards Lifesciences (NYSE:EW) from a buy rating to a hold rating in a research report report published on Wednesday morning, Marketbeat Ratings reports. They currently have $70.00 price objective on the medical research company’s stock, down from their prior price objective of $85.00.

A number of other equities analysts have also recently issued reports on EW. JPMorgan Chase & Co. cut Edwards Lifesciences from an overweight rating to a neutral rating and decreased their target price for the stock from $105.00 to $72.00 in a report on Thursday, July 25th. Canaccord Genuity Group decreased their target price on Edwards Lifesciences from $85.00 to $77.00 and set a hold rating on the stock in a report on Thursday, July 25th. StockNews.com cut Edwards Lifesciences from a buy rating to a hold rating in a report on Thursday, July 25th. Royal Bank of Canada lowered their price target on Edwards Lifesciences from $101.00 to $85.00 and set an outperform rating on the stock in a report on Thursday, July 25th. Finally, Wolfe Research upgraded Edwards Lifesciences from an underperform rating to a peer perform rating in a report on Monday, July 29th. Sixteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of Hold and an average target price of $79.82.

Edwards Lifesciences Trading Up 0.4 %

Edwards Lifesciences stock opened at $67.53 on Wednesday. The firm has a market cap of $40.69 billion, a price-to-earnings ratio of 29.11, a price-to-earnings-growth ratio of 2.85 and a beta of 1.13. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12. The firm’s 50 day moving average price is $70.89 and its two-hundred day moving average price is $83.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.66 EPS. On average, research analysts predict that Edwards Lifesciences will post 2.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock valued at $1,218,138 over the last quarter. Insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Park Avenue Securities LLC lifted its position in shares of Edwards Lifesciences by 0.5% during the 2nd quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares during the last quarter. City State Bank lifted its position in shares of Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after purchasing an additional 130 shares during the last quarter. Chapin Davis Inc. lifted its position in shares of Edwards Lifesciences by 1.7% during the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after purchasing an additional 140 shares during the last quarter. Johnson Financial Group Inc. lifted its position in shares of Edwards Lifesciences by 23.0% during the 4th quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock worth $59,000 after purchasing an additional 144 shares during the last quarter. Finally, Valley National Advisers Inc. lifted its position in shares of Edwards Lifesciences by 6.0% during the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after purchasing an additional 152 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.